| Year |
Citation |
Score |
| 2023 |
Juarez D, Buono R, Matulis SM, Gupta VA, Duong MR, Yudiono J, Paul M, Mallya S, Diep G, Hsin P, Lu A, Suh SM, Dong VM, Roberts AW, Leverson JD, ... ... Fruman DA, et al. Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL1 inhibitors. Cancer Research Communications. PMID 37956312 DOI: 10.1158/2767-9764.CRC-23-0350 |
0.339 |
|
| 2023 |
Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, ... ... Fruman DA, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Molecular Cancer. 22: 138. PMID 37596643 DOI: 10.1186/s12943-023-01827-6 |
0.329 |
|
| 2023 |
Buono R, Alhaddad M, Fruman DA. Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia. Frontiers in Oncology. 13: 1162694. PMID 37124486 DOI: 10.3389/fonc.2023.1162694 |
0.432 |
|
| 2021 |
Vo TT, Herzog LO, Buono R, Lee JS, Mallya S, Duong MR, Thao J, Gotesman M, Fruman DA. Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition. Scientific Reports. 11: 21689. PMID 34737376 DOI: 10.1038/s41598-021-00950-y |
0.505 |
|
| 2021 |
Lee BJ, Mallya S, Dinglasan N, Fung A, Nguyen T, Herzog LO, Thao J, Lorenzana EG, Wildes D, Singh M, Smith JAM, Fruman DA. Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia. Frontiers in Oncology. 11: 673213. PMID 34408976 DOI: 10.3389/fonc.2021.673213 |
0.483 |
|
| 2021 |
Chiu H, Buono R, Jackson LV, Herzog LO, Mallya S, Conn CS, Ruggero D, Fruman DA. Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function. Iscience. 24: 102748. PMID 34278258 DOI: 10.1016/j.isci.2021.102748 |
0.407 |
|
| 2020 |
Herzog LO, Walters B, Buono R, Lee JS, Mallya S, Fung A, Chiu H, Nguyen N, Li B, Pinkerton AB, Jackson MR, Schneider RJ, Ronai ZA, Fruman DA. Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax. British Journal of Cancer. PMID 33318657 DOI: 10.1038/s41416-020-01205-9 |
0.325 |
|
| 2020 |
Ishak Gabra MB, Yang Y, Li H, Senapati P, Hanse EA, Lowman XH, Tran TQ, Zhang L, Doan LT, Xu X, Schones DE, Fruman DA, Kong M. Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth. Nature Communications. 11: 3326. PMID 32620791 DOI: 10.1038/S41467-020-17181-W |
0.4 |
|
| 2020 |
Ko TK, Javed A, Lee KL, Pathiraja TN, Liu X, Malik S, Soh SX, Heng XT, Takahashi N, Tan JHJ, Bhatia R, Khng AJ, Chng WJ, Sia YY, Fruman DA, et al. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood. PMID 32157296 DOI: 10.1182/Blood.2020004834 |
0.393 |
|
| 2019 |
Fruman DA. Targeting PI3K-Gamma in Non-Hodgkin Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900215. PMID 30811291 DOI: 10.1200/Jco.19.00215 |
0.323 |
|
| 2019 |
Fruman D, Juarez D, Diep G, Nguyen F, Gupta VA, Boise LH. Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845 Blood. 134: 4413-4413. DOI: 10.1182/Blood-2019-131218 |
0.46 |
|
| 2018 |
Chiu H, Jackson LV, Oh KI, Mai A, Ronai ZA, Ruggero D, Fruman DA. The mTORC1/4E-BP/eIF4E Axis Promotes Antibody Class Switching in B Lymphocytes. Journal of Immunology (Baltimore, Md. : 1950). PMID 30530594 DOI: 10.4049/Jimmunol.1800602 |
0.506 |
|
| 2018 |
Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, ... ... Fruman DA, et al. Statins enhance efficacy of venetoclax in blood cancers. Science Translational Medicine. 10. PMID 29899021 DOI: 10.1126/Scitranslmed.Aaq1240 |
0.474 |
|
| 2018 |
Thompson JM, Alvarez A, Singha MK, Pavesic MW, Nguyen QH, Nelson LJ, Fruman DA, Razorenova OV. Targeting the mevalonate pathway suppresses VHL-deficient CC-RCC through a HIF-dependent mechanism. Molecular Cancer Therapeutics. PMID 29720560 DOI: 10.1158/1535-7163.Mct-17-1076 |
0.442 |
|
| 2018 |
Karimzadeh A, Scarfone VM, Varady E, Chao C, Grathwohl K, Fathman JW, Fruman DA, Serwold T, Inlay MA. The CD11a and Endothelial Protein C Receptor Marker Combination Simplifies and Improves the Purification of Mouse Hematopoietic Stem Cells. Stem Cells Translational Medicine. PMID 29543389 DOI: 10.1002/Sctm.17-0189 |
0.334 |
|
| 2018 |
Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, ... ... Fruman DA, et al. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade inrearranged and/ordriven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget. 9: 8027-8041. PMID 29487712 DOI: 10.18632/Oncotarget.24261 |
0.565 |
|
| 2018 |
Gotesman M, Vo TT, Herzog LO, Tea T, Mallya S, Tasian SK, Konopleva M, Fruman DA. mTOR inhibition enhances efficacy of dasatinib in-rearranged Ph-like B-ALL. Oncotarget. 9: 6562-6571. PMID 29464092 DOI: 10.18632/Oncotarget.24020 |
0.504 |
|
| 2018 |
Juarez D, Fruman DA, Fleischman AG, Brem E, Diep G, Nguyen F. Statins Enhance the Efficacy of BH3 Mimetics in Multiple Myeloma Blood. 132: 1989-1989. DOI: 10.1182/Blood-2018-99-120205 |
0.358 |
|
| 2018 |
Herzog L, Nguyen N, Chiu H, Mallya S, Ronai ZA, Fruman DA. Abstract 1886: A novel inhibitor of eIF4F protein translation complex sensitizes DLBCL cells to BCL-2 targeted therapy Cancer Research. 78: 1886-1886. DOI: 10.1158/1538-7445.Am2018-1886 |
0.513 |
|
| 2017 |
Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K Pathway in Human Disease. Cell. 170: 605-635. PMID 28802037 DOI: 10.1016/J.Cell.2017.07.029 |
0.445 |
|
| 2017 |
Chiu H, Mallya S, Nguyen P, Mai A, Jackson LV, Winkler DG, DiNitto JP, Brophy EE, McGovern K, Kutok JL, Fruman DA. The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation. Frontiers in Immunology. 8: 747. PMID 28713374 DOI: 10.3389/Fimmu.2017.00747 |
0.614 |
|
| 2017 |
Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. The Journal of Clinical Investigation. 127: 2438. PMID 28569734 DOI: 10.1172/JCI95182 |
0.818 |
|
| 2017 |
Vo TT, Lee JS, Nguyen D, Lui B, Pandori W, Khaw A, Mallya S, Lu M, Müschen M, Konopleva M, Fruman DA. mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL. Molecular Cancer Therapeutics. PMID 28566433 DOI: 10.1158/1535-7163.Mct-17-0024 |
0.567 |
|
| 2017 |
Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, Asano T, Cantley LC, Kahn CR. Positive and negative roles of p85α and p85β regulatory subunits of phosphoinositide 3-kinase in insulin signaling. The Journal of Biological Chemistry. 292: 5608. PMID 28363934 DOI: 10.1074/Jbc.A117.305602 |
0.48 |
|
| 2017 |
Fruman DA, O'Brien S. Cancer: A targeted treatment with off-target risks. Nature. PMID 28199308 DOI: 10.1038/Nature21504 |
0.463 |
|
| 2016 |
Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng SX, Realubit RB, Tatonetti NP, Karan C, Lentzsch S, Fruman DA, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3K delta and CK1 epsilon in hematological malignancies. Blood. PMID 27784673 DOI: 10.1182/Blood-2016-08-731240 |
0.476 |
|
| 2016 |
Pai C, Walsh CM, Fruman DA. Context-Specific Function of S6K2 in Th Cell Differentiation. Journal of Immunology (Baltimore, Md. : 1950). PMID 27613697 DOI: 10.4049/Jimmunol.1600167 |
0.47 |
|
| 2016 |
Hong CA, Cho SK, Edson JA, Kim J, Ingato D, Pham B, Chuang A, Fruman D, Kwon YJ. Viral/Nonviral Chimeric Nanoparticles to Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing. Acs Nano. PMID 27472284 DOI: 10.1021/Acsnano.6B04155 |
0.431 |
|
| 2016 |
Zeng Z, Wang RY, Qiu YH, Mak DH, Coombes K, Yoo SY, Zhang Q, Jessen K, Liu Y, Rommel C, Fruman DA, Kantarjian HM, Kornblau SM, Andreeff M, Konopleva M. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget. PMID 27391151 DOI: 10.18632/Oncotarget.10397 |
0.527 |
|
| 2016 |
Fruman DA. mTOR signaling: new networks for ALL. Blood. 127: 2658-9. PMID 27257176 DOI: 10.1182/Blood-2016-03-703199 |
0.468 |
|
| 2016 |
So L, Lee J, Palafox M, Mallya S, Woxland CG, Arguello M, Truitt ML, Sonenberg N, Ruggero D, Fruman DA. The 4E-BP-eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes. Science Signaling. 9: ra57. PMID 27245614 DOI: 10.1126/Scisignal.Aad8463 |
0.787 |
|
| 2016 |
Lee JS, Vo TT, Fruman DA. Targeting mTOR for the treatment of B cell malignancies. British Journal of Clinical Pharmacology. PMID 26805380 DOI: 10.1111/Bcp.12888 |
0.504 |
|
| 2016 |
Fruman DA, Lee JS, Vo TT, Bhatt S, Schatz JH, Letai A. Statins Potentiate the Cytotoxic Effect of ABT-199 in Diffuse Large B Cell Lymphoma Blood. 128: 3969-3969. DOI: 10.1182/Blood.V128.22.3969.3969 |
0.484 |
|
| 2016 |
Gotesman M, Vo TT, Mallya S, Zhang Q, Shi C, Müschen M, Weinstock DM, Mullighan C, Tasian SK, Konopleva M, Fruman DA. mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL Blood. 128: 2763-2763. DOI: 10.1182/Blood.V128.22.2763.2763 |
0.486 |
|
| 2016 |
Lee JS, Vo TT, Fruman DA. Abstract 3851: Synergy between statins and BCL-2 inhibitors in blood cancers Cancer Research. 76: 3851-3851. DOI: 10.1158/1538-7445.Am2016-3851 |
0.485 |
|
| 2015 |
Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. PMID 26460954 DOI: 10.18632/Oncotarget.6051 |
0.499 |
|
| 2015 |
Vo TT, Fruman DA. INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency. Cancer Discovery. 5: 697-700. PMID 26152921 DOI: 10.1158/2159-8290.Cd-15-0609 |
0.38 |
|
| 2015 |
Beagle BR, Nguyen DM, Mallya S, Tang SS, Lu M, Zeng Z, Konopleva M, Vo TT, Fruman DA. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. Oncotarget. 6: 2088-100. PMID 25576920 DOI: 10.18632/Oncotarget.2992 |
0.546 |
|
| 2015 |
Shi C, Han L, Zhang Q, Roberts KG, Park E, Tabe Y, Jacamo RO, Mu H, Wu S, Zhou J, Ma H, Zeng Z, Jain N, Jabbour EJ, Muschen M, ... ... Fruman D, et al. Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia Blood. 126: 2529-2529. DOI: 10.1182/Blood.V126.23.2529.2529 |
0.548 |
|
| 2015 |
Vo T, Lee JS, So L, Beagle B, Janes MR, Fruman DA. Abstract IA16: Mechanisms of resistance to mTOR inhibitors in leukemia and lymphoma Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-Ia16 |
0.844 |
|
| 2015 |
Lee JS, Tang S, Ortiz V, Fruman DA. Abstract B45: Vertical inhibition of the PI3K pathway potently sensitizes diffuse large B cell lymphoma to BCL-2 antagonism Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-B45 |
0.525 |
|
| 2015 |
Vo T, Nguyen D, Lui B, Lu M, Mallya S, Fruman D. Abstract A49: Inhibition of mTOR induces chemoresistance in B-cell acute lymphoblastic leukemia Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-A49 |
0.56 |
|
| 2014 |
Limon JJ, So L, Jellbauer S, Chiu H, Corado J, Sykes SM, Raffatellu M, Fruman DA. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proceedings of the National Academy of Sciences of the United States of America. 111: E5076-85. PMID 25385646 DOI: 10.1073/Pnas.1407104111 |
0.84 |
|
| 2014 |
Walsh CM, Fruman DA. Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling. The Journal of Clinical Investigation. 124: 3688-90. PMID 25133419 DOI: 10.1172/Jci77198 |
0.342 |
|
| 2014 |
Yea SS, So L, Mallya S, Lee J, Rajasekaran K, Malarkannan S, Fruman DA. Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. Plos One. 9: e99486. PMID 24915189 DOI: 10.1371/Journal.Pone.0099486 |
0.833 |
|
| 2014 |
Zhang Z, Eckert MA, Ali MM, Liu L, Kang DK, Chang E, Pone EJ, Sender LS, Fruman DA, Zhao W. DNA-scaffolded multivalent ligands to modulate cell function. Chembiochem : a European Journal of Chemical Biology. 15: 1268-73. PMID 24803415 DOI: 10.1002/Cbic.201402100 |
0.406 |
|
| 2014 |
Fruman DA, Cantley LC. Idelalisib--a PI3Kδ inhibitor for B-cell cancers. The New England Journal of Medicine. 370: 1061-2. PMID 24620870 DOI: 10.1056/Nejme1400055 |
0.542 |
|
| 2014 |
Mallya S, Fitch BA, Lee JS, So L, Janes MR, Fruman DA. Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1. Plos One. 9: e88865. PMID 24586420 DOI: 10.1371/Journal.Pone.0088865 |
0.832 |
|
| 2014 |
Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nature Reviews. Drug Discovery. 13: 140-56. PMID 24481312 DOI: 10.1038/Nrd4204 |
0.504 |
|
| 2014 |
Shi C, Han L, Tabe Y, Mu H, Wu S, Zhou J, Zeng Z, Fruman DA, Tasian SK, Weinstock DM, Konopleva M. Dual Targeting of JAK2 Signaling with a Type II JAK2 Inhibitor and of mTOR with a TOR Kinase Inhibitor Induces Apoptosis in CRLF2-Rearranged Ph-like Acute Lymphoblastic Leukemia Blood. 124: 3706-3706. DOI: 10.1182/Blood.V124.21.3706.3706 |
0.57 |
|
| 2014 |
Zeng Z, Wang R, Shi Y, Qiu Y, Mak DH, Coombes K, Yoo SY, Jessen K, Liu Y, Rommel C, Kantarjian HM, Kornblau SM, Fruman D, Andreeff M, Konopleva M. MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML Blood. 124: 3613-3613. DOI: 10.1182/Blood.V124.21.3613.3613 |
0.546 |
|
| 2014 |
Harutyunyan KG, Nwajei F, Zal MA, Fruman DA, Mallampati S, Sun X, Zal T, Konopleva M. The Dynamics of Stroma-Leukemia Interaction in the Hypoxic BM Niches in Vivo Blood. 124: 2396-2396. DOI: 10.1182/Blood.V124.21.2396.2396 |
0.433 |
|
| 2014 |
Vo T, Lu M, Nguyen D, Lui B, Maylla S, Fruman D. Abstract B24: Inhibition of mTOR induces multidrug resistance in B-progenitor acute lymphocytic leukemia Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B24 |
0.499 |
|
| 2014 |
Vo T, Fruman DA. Abstract 5477: mTOR inhibitors protect from apoptosis in B-ALL cells treated with chemotherapeutic drugs Cancer Research. 74: 5477-5477. DOI: 10.1158/1538-7445.Am2014-5477 |
0.554 |
|
| 2013 |
Zhang Z, Ali MM, Eckert MA, Kang DK, Chen YY, Sender LS, Fruman DA, Zhao W. A polyvalent aptamer system for targeted drug delivery. Biomaterials. 34: 9728-35. PMID 24044994 DOI: 10.1016/J.Biomaterials.2013.08.079 |
0.325 |
|
| 2013 |
Lim S, Saw TY, Zhang M, Janes MR, Nacro K, Hill J, Lim AQ, Chang CT, Fruman DA, Rizzieri DA, Tan SY, Fan H, Chuah CTH, Ong ST. Targeting of the MNK-eIF4E axis in blast crisis Chronic myeloid leukemia inhibits leukemia stem cell function Proceedings of the National Academy of Sciences of the United States of America. 110: E2298-E2307. PMID 23737503 DOI: 10.1073/Pnas.1301838110 |
0.764 |
|
| 2013 |
Yea SS, Fruman DA. Achieving cancer cell death with PI3K/mTOR-targeted therapies. Annals of the New York Academy of Sciences. 1280: 15-8. PMID 23551096 DOI: 10.1111/Nyas.12028 |
0.419 |
|
| 2013 |
So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, ... Fruman DA, et al. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. The Journal of Biological Chemistry. 288: 5718-31. PMID 23275335 DOI: 10.1074/Jbc.M112.379446 |
0.834 |
|
| 2013 |
Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 27: 586-94. PMID 23090679 DOI: 10.1038/Leu.2012.276 |
0.802 |
|
| 2012 |
Limon JJ, Fruman DA. Akt and mTOR in B Cell Activation and Differentiation. Frontiers in Immunology. 3: 228. PMID 22888331 DOI: 10.3389/Fimmu.2012.00228 |
0.594 |
|
| 2012 |
Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 120: 2679-89. PMID 22826565 DOI: 10.1182/Blood-2011-11-393934 |
0.588 |
|
| 2012 |
So L, Fruman DA. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. The Biochemical Journal. 442: 465-81. PMID 22364281 DOI: 10.1042/Bj20112092 |
0.841 |
|
| 2012 |
Soyfoo MS, Konno A, Bolaky N, Oak JS, Fruman D, Nicaise C, Takiguchi M, Delporte C. Link between inflammation and aquaporin-5 distribution in submandibular gland in Sjögren's syndrome? Oral Diseases. 18: 568-74. PMID 22320885 DOI: 10.1111/J.1601-0825.2012.01909.X |
0.653 |
|
| 2012 |
Janes MR, Fruman DA. The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia. Methods in Molecular Biology (Clifton, N.J.). 821: 251-65. PMID 22125070 DOI: 10.1007/978-1-61779-430-8_15 |
0.737 |
|
| 2011 |
Fruman DA, Rommel C. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discovery. 1: 562-72. PMID 22586681 DOI: 10.1158/2159-8290.Cd-11-0249 |
0.482 |
|
| 2011 |
Romero Rosales K, Singh G, Wu K, Chen J, Janes MR, Lilly MB, Peralta ER, Siskind LJ, Bennett MJ, Fruman DA, Edinger AL. Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins. The Biochemical Journal. 439: 299-311. PMID 21767261 DOI: 10.1042/Bj20110853 |
0.742 |
|
| 2011 |
Beagle B, Fruman DA. A lipid kinase cousin cooperates to promote cancer. Cancer Cell. 19: 693-5. PMID 21665142 DOI: 10.1016/J.Ccr.2011.05.020 |
0.44 |
|
| 2011 |
Yea SS, Fruman DA. Cell signaling. New mTOR targets Grb attention. Science (New York, N.Y.). 332: 1270-1. PMID 21659593 DOI: 10.1126/Science.1208071 |
0.389 |
|
| 2011 |
Casey SC, Nelson EL, Turco GM, Janes MR, Fruman DA, Blumberg B. B-1 cell lymphoma in mice lacking the steroid and xenobiotic receptor, SXR. Molecular Endocrinology (Baltimore, Md.). 25: 933-43. PMID 21436254 DOI: 10.1210/Me.2010-0486 |
0.776 |
|
| 2011 |
Lim S, Saw TY, Chang S, Zhang M, Janes MR, Fruman DA, Rizzieri DA, Tan S, Chuah C, Ong ST. Targeting of a Novel MNK-eIF4E-b-Catenin Axis in Blast Crisis Chronic Myelogenous Leukemia Inhibits Leukemia Stem Cell Function Blood. 118: 963-963. DOI: 10.1182/Blood.V118.21.963.963 |
0.807 |
|
| 2011 |
Fruman DA, Janes MR, Mallya S, Vu CC, Shieh MP, Lilly MB, Sender LS, Martin MB, Ren P, Liu Y, Rommel C. The TOR Kinase Inhibitor INK128 Is Effective in Pre-B Acute Lymphoblastic Leukemia Models Blood. 118: 2585-2585. DOI: 10.1182/Blood.V118.21.2585.2585 |
0.796 |
|
| 2011 |
Jessen KA, Kessler L, Kucharski J, Guo X, Staunton J, Elia M, Janes M, Lan L, Wang S, Stewart J, Darjania L, Li L, Chan K, Martin M, Ren P, ... Fruman D, et al. Abstract 4501: INK1117: A potent and orally efficacious PI3Kα-selective inhibitor for the treatment of cancer Cancer Research. 71: 4501-4501. DOI: 10.1158/1538-7445.Am2011-4501 |
0.77 |
|
| 2011 |
Beagle B, Fruman D. Abstract C71: Overcoming mechanism(s) of resistance to active-site TOR inhibitors in leukemia and lymphoma. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C71 |
0.535 |
|
| 2010 |
Vu C, Fruman DA. Target of rapamycin signaling in leukemia and lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5374-80. PMID 20826559 DOI: 10.1158/1078-0432.Ccr-10-0480 |
0.567 |
|
| 2010 |
Limon JJ, Fruman DA. B cell receptor signaling: picky about PI3Ks. Science Signaling. 3: pe25. PMID 20699473 DOI: 10.1126/Scisignal.3134Pe25 |
0.566 |
|
| 2010 |
Janes MR, Fruman DA. Targeting TOR dependence in cancer. Oncotarget. 1: 69-76. PMID 20657741 DOI: 10.18632/Oncotarget.110 |
0.753 |
|
| 2010 |
Fruman DA. Regulatory subunits of class IA PI3K. Current Topics in Microbiology and Immunology. 346: 225-44. PMID 20563711 DOI: 10.1007/82_2010_39 |
0.351 |
|
| 2010 |
Okkenhaug K, Fruman DA. PI3Ks in lymphocyte signaling and development. Current Topics in Microbiology and Immunology. 346: 57-85. PMID 20563708 DOI: 10.1007/82_2010_45 |
0.457 |
|
| 2010 |
Chen J, Limon JJ, Blanc C, Peng SL, Fruman DA. Foxo1 regulates marginal zone B-cell development. European Journal of Immunology. 40: 1890-6. PMID 20449867 DOI: 10.1002/Eji.200939817 |
0.562 |
|
| 2010 |
Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, ... Fruman DA, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Medicine. 16: 205-13. PMID 20072130 DOI: 10.1038/Nm.2091 |
0.83 |
|
| 2010 |
Fruman DA, Janes MR, Limon JJ, So L, Chen J, Martin MB, Ren P, Liu Y, Rommel C. Abstract 1798: TORC1/2 inhibitors have more potent anti-leukemic efficacy and are less immunosuppressive than rapamycin Cancer Research. 70: 1798-1798. DOI: 10.1158/1538-7445.Am10-1798 |
0.836 |
|
| 2009 |
Oak JS, Chen J, Peralta RQ, Deane JA, Fruman DA. The p85beta regulatory subunit of phosphoinositide 3-kinase has unique and redundant functions in B cells. Autoimmunity. 42: 447-58. PMID 19811262 DOI: 10.1080/08916930902911746 |
0.85 |
|
| 2009 |
Mouta-Bellum C, Kirov A, Miceli-Libby L, Mancini ML, Petrova TV, Liaw L, Prudovsky I, Thorpe PE, Miura N, Cantley LC, Alitalo K, Fruman DA, Vary CP. Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha. Developmental Dynamics : An Official Publication of the American Association of Anatomists. 238: 2670-9. PMID 19705443 DOI: 10.1002/Dvdy.22078 |
0.38 |
|
| 2009 |
Janes MR, Fruman DA. Immune regulation by rapamycin: moving beyond T cells. Science Signaling. 2: pe25. PMID 19383976 DOI: 10.1126/Scisignal.267Pe25 |
0.76 |
|
| 2009 |
Fruman DA, Bismuth G. Fine tuning the immune response with PI3K. Immunological Reviews. 228: 253-72. PMID 19290933 DOI: 10.1111/J.1600-065X.2008.00750.X |
0.54 |
|
| 2009 |
Alcázar I, Cortés I, Zaballos A, Hernandez C, Fruman DA, Barber DF, Carrera AC. p85beta phosphoinositide 3-kinase regulates CD28 coreceptor function. Blood. 113: 3198-208. PMID 19190244 DOI: 10.1182/Blood-2008-04-152942 |
0.44 |
|
| 2009 |
Oak JS, Deane JA, Kharas MG, Luo J, Lane TE, Cantley LC, Fruman DA. Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase (Proceedings of the National Academy of Sciences of the United States of America (2009) 103, 45, (16882-16887) 10.1073/pnas. 0607984103) Proceedings of the National Academy of Sciences of the United States of America. 106: 10871. DOI: 10.1073/Pnas.0905401106 |
0.794 |
|
| 2008 |
Fabre S, Carrette F, Chen J, Lang V, Semichon M, Denoyelle C, Lazar V, Cagnard N, Dubart-Kupperschmitt A, Mangeney M, Fruman DA, Bismuth G. FOXO1 regulates L-Selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase. Journal of Immunology (Baltimore, Md. : 1950). 181: 2980-9. PMID 18713968 DOI: 10.4049/Jimmunol.181.5.2980 |
0.438 |
|
| 2008 |
Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. The Journal of Clinical Investigation. 118: 3038-50. PMID 18704194 DOI: 10.1172/Jci33337 |
0.853 |
|
| 2008 |
Fruman DA, Edinger AL. Cancer therapy: staying current with AMPK. The Biochemical Journal. 412: e3-5. PMID 18466113 DOI: 10.1042/Bj20080823 |
0.431 |
|
| 2008 |
de Souza AJ, Oak JS, Jordanhazy R, DeKruyff RH, Fruman DA, Kane LP. T cell Ig and mucin domain-1-mediated T cell activation requires recruitment and activation of phosphoinositide 3-kinase. Journal of Immunology (Baltimore, Md. : 1950). 180: 6518-26. PMID 18453570 DOI: 10.4049/Jimmunol.180.10.6518 |
0.78 |
|
| 2008 |
Yusuf I, Kharas MG, Chen J, Peralta RQ, Maruniak A, Sareen P, Yang VW, Kaestner KH, Fruman DA. KLF4 is a FOXO target gene that suppresses B cell proliferation. International Immunology. 20: 671-81. PMID 18375530 DOI: 10.1093/Intimm/Dxn024 |
0.836 |
|
| 2007 |
Oak JS, Matheu MP, Parker I, Cahalan MD, Fruman DA. Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase. Biochemical Society Transactions. 35: 1109-13. PMID 17956290 DOI: 10.1042/Bst0351109 |
0.789 |
|
| 2007 |
Donahue AC, Kharas MG, Fruman DA. Measuring phosphorylated Akt and other phosphoinositide 3-kinase-regulated phosphoproteins in primary lymphocytes. Methods in Enzymology. 434: 131-54. PMID 17954246 DOI: 10.1016/S0076-6879(07)34008-1 |
0.847 |
|
| 2007 |
Oak JS, Fruman DA. Role of phosphoinositide 3-kinase signaling in autoimmunity. Autoimmunity. 40: 433-41. PMID 17729037 DOI: 10.1080/08916930701464780 |
0.8 |
|
| 2007 |
Fruman DA, Walsh CM. Signal transduction and autoimmunity: introduction. Autoimmunity. 40: 403-4. PMID 17729032 DOI: 10.1080/08916930701492740 |
0.311 |
|
| 2007 |
Donahue AC, Fruman DA. Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. European Journal of Immunology. 37: 2923-36. PMID 17724683 DOI: 10.1002/Eji.200737281 |
0.842 |
|
| 2007 |
Matheu MP, Deane JA, Parker I, Fruman DA, Cahalan MD. Class IA phosphoinositide 3-kinase modulates basal lymphocyte motility in the lymph node. Journal of Immunology (Baltimore, Md. : 1950). 179: 2261-9. PMID 17675487 DOI: 10.4049/Jimmunol.179.4.2261 |
0.831 |
|
| 2007 |
Fruman DA. The role of class I phosphoinositide 3-kinase in T-cell function and autoimmunity. Biochemical Society Transactions. 35: 177-80. PMID 17371231 DOI: 10.1042/Bst0350177 |
0.527 |
|
| 2007 |
Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE, Fruman DA. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood. 109: 2894-902. PMID 17164340 DOI: 10.1182/Blood-2006-07-038620 |
0.832 |
|
| 2007 |
Kharas MG, Yusuf I, Scarfone VM, Yang VW, Segre JA, Huettner CS, Fruman DA. KLF4 suppresses transformation of pre-B cells by ABL oncogenes. Blood. 109: 747-55. PMID 16954505 DOI: 10.1182/Blood-2006-03-011106 |
0.834 |
|
| 2006 |
Oak JS, Deane JA, Kharas MG, Luo J, Lane TE, Cantley LC, Fruman DA. Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proceedings of the National Academy of Sciences of the United States of America. 103: 16882-7. PMID 17071741 DOI: 10.1073/Pnas.0607984103 |
0.815 |
|
| 2006 |
Chen J, Yusuf I, Andersen HM, Fruman DA. FOXO transcription factors cooperate with delta EF1 to activate growth suppressive genes in B lymphocytes. Journal of Immunology (Baltimore, Md. : 1950). 176: 2711-21. PMID 16493026 DOI: 10.4049/Jimmunol.176.5.2711 |
0.791 |
|
| 2005 |
Cruz R, Hedden L, Boyer D, Kharas MG, Fruman DA, Lee-Fruman KK. S6 kinase 2 potentiates interleukin-3-driven cell proliferation. Journal of Leukocyte Biology. 78: 1378-85. PMID 16204634 DOI: 10.1189/Jlb.0405225 |
0.703 |
|
| 2005 |
Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Research. 65: 2047-53. PMID 15781610 DOI: 10.1158/0008-5472.Can-04-3888 |
0.72 |
|
| 2005 |
Brachmann SM, Yballe CM, Innocenti M, Deane JA, Fruman DA, Thomas SM, Cantley LC. Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Molecular and Cellular Biology. 25: 2593-606. PMID 15767666 DOI: 10.1128/Mcb.25.7.2593-2606.2005 |
0.768 |
|
| 2005 |
Fruman DA. Bursting with PIP3 Blood. 106: 1139-1140. DOI: 10.1182/Blood-2005-05-2040 |
0.39 |
|
| 2004 |
Zhu X, Hart R, Chang MS, Kim JW, Lee SY, Cao YA, Mock D, Ke E, Saunders B, Alexander A, Grossoehme J, Lin KM, Yan Z, Hsueh R, Lee J, ... ... Fruman DA, et al. Analysis of the major patterns of B cell gene expression changes in response to short-term stimulation with 33 single ligands. Journal of Immunology (Baltimore, Md. : 1950). 173: 7141-9. PMID 15585835 DOI: 10.4049/Jimmunol.173.12.7141 |
0.317 |
|
| 2004 |
Donahue AC, Hess KL, Ng KL, Fruman DA. Altered splenic B cell subset development in mice lacking phosphoinositide 3-kinase p85alpha. International Immunology. 16: 1789-98. PMID 15520044 DOI: 10.1093/Intimm/Dxh180 |
0.824 |
|
| 2004 |
Hess KL, Donahue AC, Ng KL, Moore TI, Oak J, Fruman DA. Frontline: The p85alpha isoform of phosphoinositide 3-kinase is essential for a subset of B cell receptor-initiated signaling responses. European Journal of Immunology. 34: 2968-76. PMID 15384044 DOI: 10.1002/Eji.200425326 |
0.861 |
|
| 2004 |
Donahue AC, Fruman DA. PI3K signaling controls cell fate at many points in B lymphocyte development and activation. Seminars in Cell & Developmental Biology. 15: 183-97. PMID 15209378 DOI: 10.1016/J.Semcdb.2003.12.024 |
0.821 |
|
| 2004 |
Deane JA, Trifilo MJ, Yballe CM, Choi S, Lane TE, Fruman DA. Enhanced T cell proliferation in mice lacking the p85beta subunit of phosphoinositide 3-kinase. Journal of Immunology (Baltimore, Md. : 1950). 172: 6615-25. PMID 15153476 DOI: 10.4049/Jimmunol.172.11.6615 |
0.825 |
|
| 2004 |
Fruman DA. Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling. Current Opinion in Immunology. 16: 314-20. PMID 15134780 DOI: 10.1016/J.Coi.2004.03.014 |
0.595 |
|
| 2004 |
Yusuf I, Zhu X, Kharas MG, Chen J, Fruman DA. Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors. Blood. 104: 784-7. PMID 15069012 DOI: 10.1182/Blood-2003-09-3071 |
0.86 |
|
| 2004 |
Fruman DA. Towards an understanding of isoform specificity in phosphoinositide 3-kinase signalling in lymphocytes. Biochemical Society Transactions. 32: 315-9. PMID 15046598 DOI: 10.1042/Bst0320315 |
0.567 |
|
| 2004 |
Deane JA, Fruman DA. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annual Review of Immunology. 22: 563-98. PMID 15032589 DOI: 10.1146/Annurev.Immunol.22.012703.104721 |
0.805 |
|
| 2004 |
Kharas MG, Deane JA, Wong S, O'Bosky KR, Rosenberg N, Witte ON, Fruman DA. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood. 103: 4268-75. PMID 14976048 DOI: 10.1182/Blood-2003-07-2193 |
0.855 |
|
| 2003 |
Maeda N, Inoshima Y, Fruman DA, Brachmann SM, Fan H. Transformation of mouse fibroblasts by Jaagsiekte sheep retrovirus envelope does not require phosphatidylinositol 3-kinase. Journal of Virology. 77: 9951-9. PMID 12941905 DOI: 10.1128/Jvi.77.18.9951-9959.2003 |
0.477 |
|
| 2003 |
Yusuf I, Fruman DA. Regulation of quiescence in lymphocytes. Trends in Immunology. 24: 380-6. PMID 12860529 DOI: 10.1016/S1471-4906(03)00141-8 |
0.795 |
|
| 2003 |
Donahue AC, Fruman DA. Proliferation and survival of activated B cells requires sustained antigen receptor engagement and phosphoinositide 3-kinase activation. Journal of Immunology (Baltimore, Md. : 1950). 170: 5851-60. PMID 12794110 DOI: 10.4049/Jimmunol.170.12.5851 |
0.839 |
|
| 2003 |
Hallmann D, Trümper K, Trusheim H, Ueki K, Kahn CR, Cantley LC, Fruman DA, Hörsch D. Altered signaling and cell cycle regulation in embryonal stem cells with a disruption of the gene for phosphoinositide 3-kinase regulatory subunit p85alpha. The Journal of Biological Chemistry. 278: 5099-108. PMID 12435753 DOI: 10.1074/Jbc.M208451200 |
0.547 |
|
| 2003 |
Yusuf I, Fruman DA. Reply to Coffer: FOXO proteins in lymphocyte quiescence Trends in Immunology. 24: 471. DOI: 10.1016/S1471-4906(03)00206-0 |
0.78 |
|
| 2002 |
Gilman AG, Simon MI, Bourne HR, Harris BA, Long R, Ross EM, Stull JT, Taussig R, Bourne HR, Arkin AP, Cobb MH, Cyster JG, Devreotes PN, Ferrell JE, Fruman D, et al. Overview of the Alliance for Cellular Signaling. Nature. 420: 703-6. PMID 12478301 DOI: 10.1038/Nature01304 |
0.389 |
|
| 2002 |
Fruman DA, Cantley LC. Phosphoinositide 3-kinase in immunological systems. Seminars in Immunology. 14: 7-18. PMID 11884226 DOI: 10.1006/Smim.2001.0337 |
0.496 |
|
| 2002 |
Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Molecular and Cellular Biology. 22: 965-77. PMID 11784871 DOI: 10.1128/Mcb.22.3.965-977.2002 |
0.48 |
|
| 2002 |
Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, Kahn CR. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. The Journal of Clinical Investigation. 109: 141-9. PMID 11781359 DOI: 10.1172/Jci13305 |
0.349 |
|
| 2002 |
Fruman DA, Ferl GZ, An SS, Donahue AC, Satterthwaite AB, Witte ON. Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 99: 359-64. PMID 11756681 DOI: 10.1073/Pnas.012605099 |
0.819 |
|
| 2001 |
Prejean C, Sarma T, Kurnasov O, Usacheva A, Hemmings B, Cantley L, Fruman DA, Morrison LA, Buller RM, Colamonici OR. Phosphatidylinositol 3-kinase confers resistance to encephalomyocarditis and herpes simplex virus-induced cell death through the activation of distinct downstream effectors Journal of Immunology. 167: 4553-4559. PMID 11591783 DOI: 10.4049/Jimmunol.167.8.4553 |
0.537 |
|
| 2000 |
Nishikawa K, Sawasdikosol S, Fruman DA, Lai J, Songyang Z, Burakoff SJ, Yaffe MB, Cantley LC. A peptide library approach identifies a specific inhibitor for the ZAP-70 protein tyrosine kinase. Molecular Cell. 6: 969-74. PMID 11090635 DOI: 10.1016/S1097-2765(05)00085-7 |
0.372 |
|
| 2000 |
Fruman DA, Mauvais-Jarvis F, Pollard DA, Yballe CM, Brazil D, Bronson RT, Kahn CR, Cantley LC. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nature Genetics. 26: 379-82. PMID 11062485 DOI: 10.1038/81715 |
0.31 |
|
| 2000 |
Fruman DA, Satterthwaite AB, Witte ON. Xid-like phenotypes: A B cell signalosome takes shape Immunity. 13: 1-3. PMID 10933389 DOI: 10.1016/S1074-7613(00)00002-9 |
0.466 |
|
| 2000 |
Satterthwaite AB, Willis F, Kanchanastit P, Fruman D, Cantley LC, Helgason CD, Humphries RK, Lowell CA, Simon M, Leitges M, Tarakhovsky A, Tedder TF, Lesche R, Wu H, Witte ON. A sensitized genetic system for the analysis of murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America. 97: 6687-92. PMID 10829070 DOI: 10.1073/Pnas.110146697 |
0.578 |
|
| 2000 |
Lu-Kuo JM, Fruman DA, Joyal DM, Cantley LC, Katz HR. Impaired kit- but not FcepsilonRI-initiated mast cell activation in the absence of phosphoinositide 3-kinase p85alpha gene products. The Journal of Biological Chemistry. 275: 6022-9. PMID 10681597 DOI: 10.1074/Jbc.275.8.6022 |
0.576 |
|
| 2000 |
Beitz LO, Fruman DA, Kurosaki T, Cantley LC, Scharenberg AM. SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. The Journal of Biological Chemistry. 274: 32662-6. PMID 10551821 DOI: 10.1074/Jbc.274.46.32662 |
0.514 |
|
| 1999 |
Fruman DA, Snapper SB, Yballe CM, Alt FW, Cantley LC. Phosphoinositide 3-kinase knockout mice: role of p85alpha in B cell development and proliferation. Biochemical Society Transactions. 27: 624-9. PMID 10917654 DOI: 10.1042/Bst0270624 |
0.342 |
|
| 1999 |
Aksoy IA, Ramsey MJ, Fruman DA, Aksoy S, Cantley LC, Tucker JD, Roberts TM. Mouse phosphoinositide 3-kinase p110alpha gene: cloning, structural organization, and localization to chromosome 3 band B. Biochemical and Biophysical Research Communications. 262: 438-42. PMID 10462494 DOI: 10.1006/Bbrc.1999.1150 |
0.397 |
|
| 1999 |
Fruman DA, Rameh LE, Cantley LC. Phosphoinositide binding domains: embracing 3-phosphate. Cell. 97: 817-20. PMID 10399908 DOI: 10.1016/S0092-8674(00)80792-8 |
0.301 |
|
| 1999 |
Gupta N, Scharenberg AM, Fruman DA, Cantley LC, Kinet JP, Long EO. The SH2 domain-containing inositol 5'-phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during FcgammaRIIb1-mediated inhibition of B cell receptor signaling. The Journal of Biological Chemistry. 274: 7489-94. PMID 10066815 DOI: 10.1074/Jbc.274.11.7489 |
0.576 |
|
| 1999 |
Fruman DA, Snapper SB, Yballe CM, Davidson L, Yu JY, Alt FW, Cantley LC. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science (New York, N.Y.). 283: 393-7. PMID 9888855 DOI: 10.1126/Science.283.5400.393 |
0.582 |
|
| 1999 |
Fruman DA, Snapper SB, Yballe CM, Mauvais-Jarvis F, Kahn CR, Alt FW, Cantley LC. PI 3-KINASE KNOCKOUT MICE: ROLE OF p85α IN B CELL DEVELOPMENT AND PROLIFERATION Biochemical Society Transactions. 27: A73-A73. DOI: 10.1042/Bst027A073C |
0.541 |
|
| 1998 |
Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annual Review of Biochemistry. 67: 481-507. PMID 9759495 DOI: 10.1146/annurev.biochem.67.1.481 |
0.353 |
|
| 1998 |
Scharenberg AM, El-Hillal O, Fruman DA, Beitz LO, Li Z, Lin S, Gout I, Cantley LC, Rawlings DJ, Kinet JP. Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. The Embo Journal. 17: 1961-72. PMID 9524119 DOI: 10.1093/Emboj/17.7.1961 |
0.5 |
|
| 1997 |
Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, Cantley LC, Roberts TM, Vogt PK. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase Science. 276: 1848-1850. PMID 9188528 DOI: 10.1126/Science.276.5320.1848 |
0.412 |
|
| 1997 |
Sagoo JK, Fruman DA, Wesselborg S, Walsh CT, Bierer BE. Competitive inhibition of calcineurin phosphatase activity by its autoinhibitory domain. The Biochemical Journal. 879-84. PMID 9003375 DOI: 10.1042/Bj3200879 |
0.353 |
|
| 1996 |
Fruman DA, Pai SY, Klee CB, Burakoff SJ, Bierer BE. Measurement of Calcineurin Phosphatase Activity in Cell Extracts Methods (San Diego, Calif.). 9: 146-54. PMID 8812656 DOI: 10.1006/Meth.1996.0020 |
0.446 |
|
| 1996 |
Wesselborg S, Fruman DA, Sagoo JK, Bierer BE, Burakoff SJ. Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). The Journal of Biological Chemistry. 271: 1274-7. PMID 8576111 DOI: 10.1074/Jbc.271.3.1274 |
0.454 |
|
| 1995 |
Fruman DA, Pai SY, Burakoff SJ, Bierer BE. Characterization of a mutant calcineurin A alpha gene expressed by EL4 lymphoma cells. Molecular and Cellular Biology. 15: 3857-63. PMID 7791792 DOI: 10.1128/Mcb.15.7.3857 |
0.391 |
|
| 1995 |
Fruman DA, Wood MA, Gjertson CK, Katz HR, Burakoff SJ, Bierer BE. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. European Journal of Immunology. 25: 563-71. PMID 7533090 DOI: 10.1002/Eji.1830250239 |
0.509 |
|
| 1994 |
Rimm IJ, Fruman DA, Abhyankar S, Sakamoto H, Orme IM, Milstone D, Seidman JG, Ferrara JL. T cell receptor (beta chain) transgenic mice have selective deficits in gamma delta T cell subpopulations. Transplant Immunology. 2: 218-24. PMID 8000850 DOI: 10.1016/0966-3274(94)90063-9 |
0.37 |
|
| 1994 |
Holländer GA, Fruman DA, Bierer BE, Burakoff SJ. Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo. Transplantation. 58: 1037-43. PMID 7526495 DOI: 10.1097/00007890-199411150-00011 |
0.47 |
|
| 1994 |
Fruman DA, Burakoff SJ, Bierer BE. Immunophilins in protein folding and immunosuppression. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 8: 391-400. PMID 7513288 DOI: 10.1096/Fasebj.8.6.7513288 |
0.331 |
|
| 1994 |
Pai S, Fruman D, Leong T, Neuberg D, Rosano T, McGarigle C, Antin J, Bierer B. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A Blood. 84: 3974-3979. DOI: 10.1182/Blood.V84.11.3974.Bloodjournal84113974 |
0.348 |
|
| 1993 |
Bierer BE, Holländer G, Fruman D, Burakoff SJ. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Current Opinion in Immunology. 5: 763-73. PMID 7694595 DOI: 10.1016/0952-7915(93)90135-F |
0.363 |
|
| 1992 |
Fruman DA, Mather PE, Burakoff SJ, Bierer BE. Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas. European Journal of Immunology. 22: 2513-7. PMID 1382988 DOI: 10.1002/Eji.1830221008 |
0.471 |
|
| 1992 |
Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proceedings of the National Academy of Sciences of the United States of America. 89: 3686-90. PMID 1373887 DOI: 10.1073/Pnas.89.9.3686 |
0.441 |
|
| Show low-probability matches. |